globenewswire news

TSRF-786C demonstrates sub-nanomolar affinity, a favorable in vitro safety and immunogenicity profile, and broad potential across ADCs, bispecifics, and cell therapies

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Tasrif Pharmaceutical, LLC today announced the grant of its second U.S. Patent, expanding its intellectual property targeting the Poliovirus Receptor (CD155/PVR). Together with Tasrif’s foundational issued U.S. patent, this expanded portfolio covers a proprietary panel of humanized monoclonal antibodies and antigen-binding fragments including the lead candidate, TSRF-786C IgG4 (S241P), humanized using Abzena’s Composite Human Antibody™ (CHAb) platform. Tasrif is also leveraging its patented CD155-binding platform to engineer next-generation modalities, including Antibody-Drug Conjugates (ADCs), Bispecifics, T-cell engagers, CAR-T, and CAR-NK cell therapies. National Phase patent applications originating from Tasrif's PCT international application are currently pending in Japan, Europe, Canada, Australia, and China.

To address central nervous system (CNS) malignancies, Tasrif evaluated its CD155 targeting platform in a syngeneic GL261 glioblastoma mouse model using a surrogate anti-mouse CD155 antibody. The study confirmed in vivo target engagement and tumor-specific accumulation within GL261 brain tumors. Building on this proof-of-concept, Tasrif is advancing brain-penetrating bispecific antibodies—comprising humanized Anti-CD155 × Anti-Transferrin Receptor (Anti-CD155 × Anti-TfR)—specifically engineered to cross the blood-brain barrier for CNS indications.

For systemic cancer indications, lead candidate TSRF-786C exhibits sub-nanomolar binding affinity for CD155, as confirmed by Surface Plasmon Resonance (SPR). Selection of TSRF-786C was validated through extensive preclinical profiling, demonstrating precise target specificity via the Retrogenix® Cell Microarray Platform Assay, low immunogenicity via Abzena’s EpiScreen® DC T-cell assay, a favorable profile on Cytokine Release Assay (CRA), and excellent thermostability and freeze-thaw resilience. Crucially, TSRF-786C demonstrates robust cross-reactivity with non-human primate (NHP) CD155, enabling planned IND-enabling safety and toxicology studies.

In pilot studies using humanized mouse models of pancreatic and lung cancer, TSRF-786C successfully modulated the key PVR (CD155)–DNAM-1 (CD226) immune axis. Treatment with TSRF-786C yielded a statistically significant increase in the percentage of CD226 (DNAM-1) positive T cells (both CD4 and CD8) within the lung tumor microenvironment, as well as a statistically significant increase in the percentage of CD226 (DNAM-1) positive tumor-infiltrating Natural Killer (NK) cells in the pancreatic tumor microenvironment. Notably, TSRF-786C did not alter local PD-1 expression, thus providing a strong rationale for combination strategies with anti-PD-1 therapies. These data support the ongoing preclinical development of TSRF-786C, with IND-enabling safety and toxicology evaluations for systemic cancers.

About TSRF-786C IgG4 (S241P)

TSRF-786C IgG4 (S241P) is a humanized monoclonal antibody currently under preclinical development for the treatment of cancers that express CD155.

About Tasrif Pharmaceutical, LLC

Tasrif Pharmaceutical, LLC is a preclinical-stage biopharmaceutical company incorporated in New York. Tasrif’s mission is to improve and prolong the lives of cancer patients.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements, including declarations regarding expectations that involve substantial risks and uncertainties. In some cases, one can identify forward-looking statements by terminology such as "may," "will," "should," "would," "could," "expects," "plans," "anticipates," "believes," "predicts," "projects," "intends," "potential," or "continue," although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to inherent risks and uncertainties in predicting future results and conditions that could cause actual results to differ materially from those projected in these forward-looking statements. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition, liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:

Tasrif Pharmaceutical, LLC

Website: tasrifpharmaceutical.org

Email: info@tasrifpharmaceutical.com

LinkedIn: linkedin.com/company/tasrif-pharmaceutical